The incidence of type 2 diabetes associated chronic kidney disease (T2DM and CKD) is high and it is the leading cause of end-stage renal disease (ESRD) and cardiovascular death. Previous drugs for the treatment of T2DM and CKD mainly target the pathogenesis of hemodynamic abnormalities and metabolic disorders, while there are few drugs involving anti-inflammatory and anti-fibrosis mechanisms. Finerenone, a new non-steroidal mineralocorticoid receptor antagonist (nsMRA), has achieved cardiorenal protection in T2DM and CKD by inhibiting inflammation and fibrosis. This article reviews the efficacy, safety and related mechanisms of finerenone in the treatment of T2DMand CKD